<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1704233558
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DENACIF 125 mg/5 ml Suspension
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFDINIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharma International Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Denacif &reg;</strong> contains the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration.<br />To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial<br />drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by<br />susceptible bacteria.<br /><strong>Denacif &reg;</strong> is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the<br />designated microorganisms in the conditions listed below:<br /><strong>Adults and Adolescents</strong><br />Community-Acquired Pneumonia.<br />Acute Exacerbations of Chronic Bronchitis.<br />Acute Maxillary Sinusitis.<br />Pharyngitis/Tonsillitis.<br />Uncomplicated Skin and Skin Structure Infections.<br /><strong>Pediatric Patients</strong><br />Acute Bacterial Otitis Media.<br />Pharyngitis/Tonsillitis.<br />Uncomplicated Skin and Skin Structure Infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Denacif </strong><strong>&reg;</strong><strong>:</strong></p><p dir="ltr">&middot; If you are allergic to cefdinir or any of the other ingredients of this medicine.</p><p dir="ltr">&middot; If you are allergic to the cephalosporin class of antibiotics.</p><p dir="ltr">Signs of an allergic reaction include a rash, swallowing or breathing problems, and swelling of the lips, face, throat and tongue.</p><p dir="ltr">Do not take this medicine if the above applies to you. If you are not sure, talk to your doctor or your pharmacist before taking <strong>Denacif </strong><strong>&reg;</strong></p><p dir="ltr">Warnings and Precautions Before taking Denacif &reg;:</p><p dir="ltr">&middot; Tell your doctor and pharmacist if you are allergic to cefdinir or any other cephalosporin antibiotic such as cefaclor ,</p><p dir="ltr">cefadroxil, cefazolin, cefditoren, cefepime, cefixime, cefotaxime, cefotetan, cefoxitin, cefpodoxime, cefprozil, ceftaroline, ceftazidime, ceftibuten, ceftriaxone, cefuroxime or cephalexin; penicillin antibiotics; or any other medications. Also tell your doctor if you are allergic to any of the ingredients in <strong>Denacif </strong><strong>&reg; &nbsp;</strong>capsules, or suspension. Ask your pharmacist for a list of the ingredients.</p><p dir="ltr">&middot; Tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements,</p><p dir="ltr">and herbal products you are taking or plan to take. Be sure to mention probenecid. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.</p><p dir="ltr">&middot; If you are taking antacids containing magnesium or aluminum, iron supplements, or multivitamins that contain iron, take</p><p dir="ltr">them 2 hours before or 2 hours after <strong>Denacif </strong><strong>&reg;</strong>.</p><p dir="ltr">&middot; Tell your doctor if you have or have ever had gastrointestinal disease (GI; affecting the stomach or intestines), especially colitis (condition that causes swelling in the lining of the colon [large intestine]), or kidney disease.</p><p>&middot; Tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking <strong>Denacif</strong><strong> </strong><strong>&reg;</strong>, call your doctor.</p><p>&middot; If you have diabetes, you should know that <strong>Denacif </strong><strong>&reg; &nbsp;</strong>suspension contains sucrose (sugar).</p><p>Children patients</p><p>Safety and efficacy in neonates and infants less than 6 months of age have not been established.</p><p>Elderly patients</p><p>Dose adjustment in elderly patients is not necessary unless renal function is markedly compromised.</p><p>Other medicines and Denacif &reg;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Some medicines may be affected by <strong>Denacif </strong><strong>&reg; &nbsp;</strong>or they may affect how well <strong>Denacif </strong><strong>&reg; &nbsp;</strong>will work. Tell your doctor or pharmacist if you are already taking:</p><p>Antacids (Aluminum- or Magnesium-Containing) - If antacids are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the antacid.</p><p>Probenecid - As with other &beta;-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir.</p><p>Iron Supplements and Foods Fortified with Iron - If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement.</p><p>Laboratory Tests</p><p>If you require any tests, while taking this medicine, please make sure your doctor knows that you are taking <strong>Denacif </strong><strong>&reg;</strong>. A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.</p><p>The administration of cefdinir may result in a false-positive reaction for glucose in urine using alkaline copper sulfate, Benedict&rsquo;s solution, or Fehling&rsquo;s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.</p><p>Cephalosporins are known to occasionally induce a positive direct Coombs&rsquo; test.</p><p>Denacif &reg; &nbsp;with food and drink</p><p><strong>Denacif </strong><strong>&reg; &nbsp;</strong>capsules and oral suspension may be taken without regard to food.</p><p dir="ltr">Pregnancy and breast-feeding Pregnancy</p><p dir="ltr">There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p><p dir="ltr">Breast-feeding</p><p dir="ltr">Cefdinir was not detected in human breast milk.</p><p dir="ltr">Please ask your doctor for advice before taking any medicine.</p><p dir="ltr">Important information about some of the ingredients of Denacif &reg; &nbsp;Suspension</p><p dir="ltr"><strong>Denacif </strong><strong>&reg; &nbsp;</strong>suspension contains sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">Recommended dose: Adults:</p><p dir="ltr">The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as BID dosing. Once- daily dosing has not been studied in pneumonia or skin infections; therefore, <strong>Denacif </strong><strong>&reg; &nbsp;</strong>capsules should be administered twice daily in these infections. <strong>Denacif </strong><strong>&reg; &nbsp;</strong>capsules may be taken without regard to meals.</p><p dir="ltr"><strong>Adults&nbsp;and Adolescents (Age 13 Years and Older)</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Type of Infection</strong></p></td><td><p><strong>Dosage</strong></p></td><td><p><strong>Duration</strong></p></td></tr><tr><td><p>Community-Acquired Pneumonia</p></td><td><p>300 mg q12h</p></td><td><p>10 days</p></td></tr><tr><td><p>Acute Exacerbations of Chronic Bronchitis</p></td><td><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Acute Maxillary Sinusitis</p></td><td><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Pharyngitis/Tonsillitis</p></td><td><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Uncomplicated Skin and Skin Structure Infections</p></td><td><p>300 mg q12h</p></td><td><p>10 days</p></td></tr></tbody></table><p dir="ltr"><strong>Children:</strong></p><p dir="ltr">The recommended dosage and duration of treatment for infections in pediatric patients are described in the following chart; the total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in skin infections; therefore, <strong>Denacif </strong><strong>&reg; &nbsp;</strong>for oral suspension should be administered twice daily in this infection. <strong>Denacif </strong><strong>&reg; &nbsp;</strong>for oral suspension may be administered without regard to meals.</p><p><strong>(Pediatric Patients (Age 6 months through 12 Years</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Type of Infection</strong></p></td><td><p><strong>Dosage</strong></p></td><td><p><strong>Duration</strong></p></td></tr><tr><td><p>Acute Bacterial Otitis Media</p></td><td><p>7 mg/kg q12h</p><p>or</p><p>14 mg/kg q24h</p></td><td><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Acute Maxillary Sinusitis</p></td><td><p>7 mg/kg q12h</p><p>or</p><p>14 mg/kg q24h</p></td><td><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Pharyngitis/Tonsillitis</p></td><td><p>7 mg/kg q12h</p><p>or</p><p>14 mg/kg q24h</p></td><td><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Uncomplicated Skin and Skin</p></td><td><p>7 mg/kg q12h</p></td><td><p>10 days</p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>If you take more Denacif &reg; than you should</strong><br />Information on cefdinir overdosage in humans is not available.<br />Toxic signs and symptoms following overdosage with other &beta;-lactam antibiotics have included nausea, vomiting,<br />epigastric distress, diarrhea, and convulsions. Hemodialysis removes cefdinir from the body.<br /><strong>If you forget to take Denacif &reg;</strong><br />If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. Do not take a double dose<br />to make up for a forgotten dose.<br /><strong>If you stop taking Denacif &reg;</strong><br />Skipping doses or not completing the full course of therapy may:<br />Decrease the effectiveness of the immediate treatment.<br />Increase the likelihood that bacteria will develop resistance and will not be treatable by cefdinir or other antibacterial<br />drugs in the future.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>Cefdinir Capsules (Adult and Adolescent Patients)</strong><br />In clinical trials, adult and adolescent patients were treated with the recommended dose of cefdinir capsules (600 mg/day).<br />Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. Some<br />patients discontinued medication due to adverse events thought to be associated with cefdinir. The discontinuations were<br />primarily for gastrointestinal disturbances, usually diarrhea or nausea, and small number of patients were discontinued due<br />to rash thought related to cefdinir administration.<br />The following adverse events were thought to be related to cefdinir capsules in multiple-dose clinical trials:<br /><strong>Adverse Events Associated with Cefdinir Capsules in Adult and Adolescent Patients</strong><br /><strong>Incidence &ge; 1%:</strong> diarrhea, vaginal moniliasis, nausea, headache, abdominal pain, vaginitis.<br /><strong>Incidence &lt; 1% but &gt; 0.1%:</strong> Rash, dyspepsia, flatulence, vomiting, abnormal stools, anorexia, constipation, dizziness,<br />dry mouth, asthenia, insomnia, leukorrhea, moniliasis, pruritus, somnolence.<br />The following laboratory value changes of possible clinical significance, irrespective of relationship to therapy with<br />cefdinir, were seen during clinical trials:<br /><strong>Laboratory Value Changes Observed with Cefdinir Capsules in Adult and Adolescent Patients</strong><br />Incidence &ge; 1%: increase the level of urine leukocytes, increase the level of urine protein, increase the level of<br />Gamma-glutamyltransferase, increase the level of lymphocytes, decrease the level of lymphocytes, increase the level<br />microhematuria.<br /><strong>Incidence &lt; 1% but &gt; 0.1%</strong>: increase the level of Glucose, increase the level of Urine glucose, increase the count of<br />White blood cells, decrease the count of White blood cells, increase the level of alanine aminotransferase (ALT), increase<br />of eosinophils, increase of urine specific gravity, decrease of urine specific gravity, decrease the level of bicarbonate,<br />increase the level of Phosphorus, decrease the level of Phosphorus, increase the level of aspartate aminotransferase<br />(AST), increase the level of alkaline phosphatase, increase the level of blood urea nitrogen (BUN), decrease the level<br />of Hemoglobin, increase the level of polymorphonuclear neutrophils (PMNs), decrease the level of polymorphonuclear<br />neutrophils (PMNs), increase the level of bilirubin, increase the level of Lactate dehydrogenase, increase the count of<br />platelets, increase the level of potassium, increase of urine pH.<br /><strong>Cefdinir for Oral Suspension (Pediatric Patients)</strong><br />In clinical trials, pediatric patients were treated with the recommended dose of cefdinir suspension (14 mg/kg/day). Most<br />adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. Some patients<br />discontinued medication due to adverse events considered to be associated with cefdinir therapy. Discontinuations were<br />primarily for gastrointestinal disturbances, usually diarrhea, and small number of patients were discontinued due to rash<br />thought related to cefdinir administration.<br />The following adverse events were thought to be related to cefdinir suspension in multiple-dose clinical trials:<br /><strong>ADVERSE EVENTS ASSOCIATED WITH CEFDINIR SUSPENSION IN PEDIATRIC PATIENTS</strong><br /><strong>Incidence &ge; 1%</strong>: Diarrhea, Rash, Vomiting.<br /><strong>Incidence &lt; 1% but &gt; 0.1%</strong>: Cutaneous moniliasis, abdominal pain, leukopenia&dagger;, vaginal moniliasis, vaginitis, abnormal<br />stools, dyspepsia, hyperkinesia, increased AST, maculopapular rash, nausea.<br />&dagger; Laboratory changes were occasionally reported as adverse events.<br /><strong>NOTE: Rates of diarrhea and rash were higher in the youngest pediatric patients.<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in<br />this leaflet.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep out of the reach and sight of children.<br />Do not use <strong>Denacif &reg;</strong> Capsules &amp; Oral Suspension after the expiry date (EXP) which is stated on the label and the carton.<br />The expiry date refers to the last day of that month.<br /><strong>Denacif &reg;</strong> Capsules &amp; Oral Suspension: Store below 30&deg;C.<br /><strong>After reconstitution, the suspension should be used within 14 days</strong>.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of<br />medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is cefdinir.<br />The other ingredients for capsules are microcrystalline cellulose, sodium lauryl sulphate, croscarmellose sodium,<br />magnesium stearate.<br />The other ingredients for powder for oral suspension are Sucrose, methyl paraben (fine), xanthan gum, microcrystalline<br />cellulose &amp; Carboxymethyl cellulose sodium, citric acid.H2O (fine), tutti fruiti powder flavor, FD&amp;C Red # 40,<br />polysorbate 20, simethicone oil LVA, colloidal silicon dioxide, Isopropanol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Hard gelatin capsule with black opaque cap printed in white color with MD, Red opaque body printed in white color with
Denacif 300, size zero intended for oral use.
Pack size:
10 Capsules in HDPE bottle.
Denacif ® Powder for Oral Suspension
Dry state: peach to light pink granules with tutti fruity flavor
Reconstituted powder: pink suspension with tutti fruity flavor.
Pack size:
50 ml and 100 ml.
How to prepare the suspension:
Invert the bottle and shake powder loose.
Add boiled and cooled water in two portions up to the mark indicated on the bottle; shake after each addition until a
homogeneous suspension is achieved.
After reconstitution, the suspension should be used within 14 days.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by : Pharma International Company - Jordan</strong><br /><strong>Packed by :Med City Pharma - KSA<br />MAH is : Med City Pharma - KSA</strong><br />Tel: 00966920003288<br />Fax: 00966126358138<br />Mobile: 00966555786968<br />P.O .Box: 42512 - Jeddah 21551<br />E-mail: MD.admin@Axantia.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي <strong>ديناسيف&reg;</strong> على المادة الفعالة سيفدينير، وهي من المضادات الحيوية واسعة الطيف، و محضر عن طريق التصنيع الكيميائي من مواد&nbsp;طبيعية من مجموعة السيفالوسبورينات، ومعد للاستخدام عن طريق الفم.<br />لتقليل حصول مقاومة البكتيريا للدواء وللمحافظة على فعالية سيفدينير وغيره من الأدوية المضادة للبكتيريا، يجب استعمال سيفدينير فقط لعلاج<br />أو الوقاية من الالتهابات المثبت حصولها نتيجة للإصابة بالبكتيريا الحساسة لهذا الدواء أو المشتبه فيها بقوة.<br />يوصف<strong> ديناسيف&reg;&nbsp;</strong>لعلاج المرضى الذين يعانون من التهابات معتدلة إلى متوسطة ناتجة عن سلالات بكتيريا معينة حساسة للدواء في الحالات&nbsp;التالية:<br /><strong>البالغون والمراهقون</strong><br />التهاب الرئة المكتسب من المجتمع.<br />التفاقم الحاد لالتهاب القصبات المزمن.<br />التهاب الجيوب الفكية الحاد.<br />التهاب البلعوم/التهاب اللوزتين.<br />التهابات الجلد وتركيباته غير المعقدة.<br /><strong>المرضى الأطفال</strong><br />التهاب الأذن الوسطى الحاد الناتج عن البكتيريا.<br />التهاب البلعوم/التهاب اللوزتين.<br />التهابات الجلد وتركيباته غير المعقدة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>الحالات التي يجب أن لا تأخذ فيها ديناسيف&reg;:</strong><br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من تحسس لسيفدينير أو لأي من المكونات الأخرى في هذا الدواء.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من تحسس للمضادات الحيوية من مجموعة السيفالوسبورينات.<br />علامات التحسس تتضمن: طفح جلدي، مشاكل في البلع أو التنفس، تورم في الشفاه ، الوجه ، الحلق و اللسان.<br />&nbsp;لاتتناول هذا الدواء في حال انطبق عليك أي من الأعراض المذكورة. استشر الطبيب أو الصيدلاني قبل تناول <strong>ديناسيف&reg;</strong>&nbsp;في حال لم تكن متأكدا.&nbsp;<br /><strong>الاحتياطات والمحاذير<br />قبل تناول ديناسيف&reg;:</strong><br />&bull;&thinsp;أخبر طبيبك أو الصيدلي إذا كنت تعاني من الحساسية لسيفدينير أو لأي مضادات حيوية أخرى من مجموعة السيفالوسبورينات مثل سيفاكلور،<br />سيفادروكسيل، سيفازولين، سيفديترون، سيفيبيم، سيفيكسيم، سيفوتاكسيم، سيفوتيتان، سيفوكسيتين، سيفبودوكسيم، سيفبروزيل، سيفتارولين،<br />سيفتازيديم، سيفتيبيوتين، سيفترياكسون، سيفوروكسيم أو سيفالكسين، المضادات الحيوية من مجموعة البنسلينات، أو أي أدوية أخرى. أخبر طبيبك&nbsp;أيضا إذا كنت تعاني من تحسس لأي مكونات في كبسولات أو معلق <strong>ديناسيف&reg;</strong> اسأل الصيدلي عن قائمة مكونات هذا الدواء.&nbsp;<br />&bull;&thinsp;أخبر طبيبك والصيدلي عن الأدوية الموصوفة لك من قبل الطبيب وتلك التي يتم الحصول عليها بدون وصفة طبية، الڤيتامينات، المكملات<br />الغذائية، والمستحضرات العشبية التي تتناولها أو تخطط لتناولها. تأكد من ذكر بروبينسيد في حال تناوله. قد يحتاج الطبيب إلى تغيير جرعة<br />الأدوية التي تتناولها أو مراقبة حصول الآثار الجانبية لديك بحذر.<br />&bull;&thinsp;إذا كنت تتناول مضادات الحموضة المحتوية على المغنيسيوم أو الألومنيوم، مكملات الحديد، أو الڤيتامينات المتعددة التي تحتوي على الحديد، تناولها قبل أو بعد ساعتين من تناول <strong>ديناسيف&reg;.</strong><br />&bull;&thinsp;أخبر طبيبك إذا كنت تعاني أو عانيت في السابق من مرض معدي معوي (يؤثر على المعدة أو الأمعاء)، خصوصا التهاب القولون (حالة تسبب تورم بطانة القولون (الأمعاء الغليظة ))، أو مرض في الكلى.<br />&nbsp;&bull;&thinsp;أخبري طبيبك إذا كنت حاملا، تخططين للحمل، أو كنت مرضعة. إذا حصل الحمل خلال فترة تناول <strong>ديناسيف&reg;</strong>&nbsp;اتصلي مع طبيبك.&nbsp;<br />&nbsp;&bull;&thinsp;إذا كنت تعاني من داء السكري، يجب أن تكون على دراية أن <strong>ديناسيف&reg;&nbsp;</strong>معلق للشرب يحتوي على السكروز (أحد السكريات).<br /><strong>المرضى الأطفال</strong><br />لم تثبت سلامة وفعالية استعمال هذا الدواء للأطفال حديثي الولادة والرضع الأقل من 6 شهور.<br /><strong>المرضى كبار السن</strong><br />لا يوجد حاجة لتعديل جرعة المرضى كبار السن ما لم يعاني من قصور في وظيفة الكلى بشكل ملحوظ.<br /><strong>تناول أدوية أخرى مع ديناسيف&reg;&nbsp;</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو من الممكن أن تتناول أي أدوية أخرى.<br />&nbsp;قد يتأثر مفعول بعض الأدوية باستعمال <strong>ديناسيف&reg;</strong>&nbsp;أو قد تؤثر بعض الأدوية على طريقة عمل <strong>ديناسيف&reg;</strong> أخبر الطبيب أو الصيدلي إذا كنت تتناول حالياً أي مما يلي:<br />مضادات الحموضة (المحتوية على الألومنيوم أو المغنيسيوم) - إذا كانت هناك حاجة لتناول مضادات الحموضة خلال فترة العلاج باستعمال سيفدينير، يجب تناول سيفدينير قبل أو بعد ساعتين على الأقل من تناول مضادات الحموضة.<br />بروبينسيد - كما هو الحال مع المضادات الحيوية الأخرى من مجموعة بيتا لاكتام يعمل بروبينسيد على تثبيط التخلص من سيفدينير عن طريق الكلى.<br />مكملات الحديد والأغذية المدعمة بالحديد - إذا كانت هناك حاجة لتناول مكملات الحديد خلال فترة العلاج باستعمال سيفدينير، يجب تناول سيفدينير قبل أو بعد ساعتين على الأقل من تناول مكملات الحديد.<br /><strong>تناول ديناسيف&reg; مع الطعام و الشراب&nbsp;</strong><br />&nbsp;من الممكن تناول كبسولات أو معلق&nbsp;<strong>ديناسيف&reg;</strong> مع أو بدون تناول الطعام.<br /><strong>الحمل و الرضاعة الطبيعية<br />الحمل</strong><br />لا تتوفر دراسات كافية ومضبوطة بشكل جيد للنساء الحوامل. لأن الدراسات المتعلقة بتكاثر الحيوانات لا تمثل دائما استجابة الإنسان، يجب<br />استعمال هذا الدواء خلال فترة الحمل فقط إذا كان هناك حاجة ملحة.<br /><strong>الرضاعة الطبيعية</strong><br />لم يظهر سيفدينير في حليب الثدي عند الإنسان.<br />الرجاء استشارة الطبيب قبل تناول أي دواء.<br /><strong>معلومات مهمة حول بعض مكونات معلق ديناسيف&reg;</strong><br />يحتوي معلق <strong>ديناسيف&reg;</strong> على السكروز. إذا أخبرت من قبل الطبيب بأنك لا تستطيع تحمل بعض أنواع السكريات، استشر طبيبك قبل تناول&nbsp;هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائما كما أخبرك طبيبك. يجب عليك التحقق من طبيبك أو الصيدلي إذا لم تكن متأكدا من كيفية استخدام الدواء.<br /><strong>الجرعة الموصى بها:<br />البالغون:</strong><br />يتم وصف الجرعة الموصى بها ومدة العلاج للالتهابات عند البالغين والمراهقين كما هو موضح في الجدول التالي، تبلغ الجرعة اليومية الكلية لعلاج جميع الالتهابات 600 ملغم. إن جرعة مرة واحدة يوميا لمدة 10 أيام لها نفس فعالية جرعة مرتين يومياً. لم يتم دراسة جرعة مرة واحدة&nbsp;يوميا&nbsp;في حالة التهابات الرئتين أو الجلد، لذلك، يجب تناول كبسولات <strong>ديناسيف&reg; </strong>مرتين يوميا عند الإصابة بهذه الالتهابات<br />من الممكن تناول كبسولات <strong>ديناسيف&reg;&nbsp;</strong>مع أو بدون تناول الطعام.<br /><strong>البالغون والمراهقون (الذين تبلغ أعمارهم 13 عاما و أكبر)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>مدة</strong><strong> </strong><strong>العلاج</strong></p></td><td><p><strong>الجرعة</strong></p></td><td><p><strong>نوع</strong><strong> </strong><strong>الالتهاب</strong></p></td></tr><tr><td><p>10&nbsp;&nbsp; أيام</p></td><td><p dir="rtl">300 ملغم &nbsp;كل 12 ساعة&nbsp; &nbsp;&nbsp;</p></td><td><p>التهاب الرئة المكتسب من المجتمع</p></td></tr><tr><td><p>&nbsp;5 إلى 10 أيام</p><p>&nbsp;</p><p>&nbsp;10&nbsp;&nbsp; أيام</p></td><td><p dir="rtl">&nbsp;300 ملغم &nbsp;كل 12 ساعة</p><p>أو</p><p dir="rtl">600ملغم كل 24 ساعة</p></td><td><p>التفاقم الحاد لالتهاب القصبات المزمن</p></td></tr><tr><td><p>&nbsp;10&nbsp; أيام</p><p>&nbsp;</p><p>&nbsp;10&nbsp; أيام</p></td><td><p dir="rtl">300 ملغم &nbsp;كل 12 ساعة</p><p>أو</p><p dir="rtl">600ملغم كل 24 ساعة</p></td><td><p>التهاب الجيوب الفكية الحاد</p></td></tr><tr><td><p>&nbsp;5 إلى 10 أيام</p><p>&nbsp;</p><p>&nbsp;10&nbsp;&nbsp; أيام</p></td><td><p dir="rtl">300 ملغم &nbsp;كل 12 ساعة</p><p>أو</p><p dir="rtl">600ملغم كل 24 ساعة</p></td><td><p>التهاب البلعوم/التهاب اللوزتين</p></td></tr><tr><td><p>&nbsp;10&nbsp; أيام</p></td><td><p dir="rtl">300 ملغم &nbsp;كل 12 ساعة</p></td><td><p>التهابات الجلد وتركيباته غير المعقدة</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p><strong>الأطفال:</strong><br />يتم وصف الجرعة الموصى بها ومدة العلاج للالتهابات عند المرضى الأطفال كما هو موضح في الجدول التالي، تبلغ الجرعة اليومية الكلية<br />لعلاج جميع الالتهابات 14 ملغم/كغم، لتصل إلى الجرعة القصوى 600 ملغم كل يوم. إن جرعة مرة واحدة يوميا لمدة 10 أيام لها نفس فعالية<br />مرتين يوميا . لم يتم دراسة جرعة مرة واحدة يوميا في حالة التهابات الجلد، لذلك، يجب تناول معلق <strong>ديناسيف&reg;</strong>&nbsp;جرعة مرتين يومياً عند الإصابة&nbsp;بهذا الالتهاب. من الممكن تناول معلق ديناسيف بدون او مع تناول الطعام.</p><p><strong>المرضى الأطفال (الذين تبلغ أعمارهم 6 أشهر- 12 عاما)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>مدة</strong><strong> </strong><strong>العلاج</strong></p></td><td><p><strong>الجرعة</strong></p></td><td><p><strong>نوع</strong><strong> </strong><strong>الالتهاب</strong></p></td></tr><tr><td><p>&nbsp;5 إلى 10 أيام</p><p>&nbsp;</p><p>&nbsp;10&nbsp;&nbsp; أيام</p></td><td><p>7 ملغم/كغم كل 12 ساعة</p><p>أو</p><p>14 ملغم /كغم كل 24 ساعة</p></td><td><p>التهاب الأذن الوسطى الحاد الناتج</p><p>عن البكتيريا</p></td></tr><tr><td><p>&nbsp;10&nbsp; أيام</p><p>&nbsp;</p><p>&nbsp;10&nbsp; أيام</p></td><td><p>7 ملغم/كغم كل 12 ساعة</p><p>أو</p><p>14 ملغم /كغم كل 24 ساعة</p></td><td><p>التهاب الجيوب الفكية الحاد</p></td></tr><tr><td><p>&nbsp;5 إلى 10 أيام</p><p>&nbsp;</p><p>&nbsp;10&nbsp;&nbsp; أيام</p></td><td><p>7 ملغم/كغم كل 12 ساعة</p><p>أو</p><p>14 ملغم /كغم كل 24 ساعة</p></td><td><p>التهاب البلعوم/التهاب اللوزتين</p></td></tr><tr><td><p>&nbsp;10&nbsp; أيام</p></td><td><p>7 ملغم/كغم كل 12 ساعة</p></td><td><p>التهابات الجلد وتركيباته غير المعقدة</p></td></tr></tbody></table><p dir="ltr">&nbsp; <strong>اذا تناولت ديناسيف&reg;&nbsp;أكثر مما يجب</strong><br />لا تتوفر معلومات عن فرط جرعة سيفدينير عند الإنسان.<br />تتضمن علامات وأعراض السمية التي تتبع فرط جرعة المضادات الحيوية من مجموعة البيتا لاكتام شعور بالغثيان، قيء، ضيق شرسوفي،<br />إسهال و تشنجات. يتم إزالة سيفدينير من الجسم عن طريق الديلزة الدموية.</p><p>&nbsp;<strong>&reg;إذا نسيت تناول&nbsp;ديناسيف</strong><br />إذا نسيت تناول جرعة، تناولها حال تذكرك ما لم يحين موعد الجرعة التالية. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.<br /><strong>&reg;إذا توقفت عن تناول ديناسيف</strong><br />ترك جرعات أو عدم إكمال العلاج قد يؤدي إلى ما يلي:<br />تقل فاعلية العلاج المباشر.<br />زيادة احتمالية نمو البكتيريا المقاومة للدواء وعدم قابلية العلاج باستعمال سيفدينير أو الأدوية الأخرى المضادة للبكتيريا في المستقبل.<br />إذا كان لديك أية أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يتسبب في آثار جانبية، على الرغم من أنها لا تحصل عند الجميع.<br /><strong>كبسولات سيفدينير (المرضى البالغين والمراهقين)</strong><br />في التجارب السريرية، تم علاج البالغين و المراهقين بالجرعة الموصى بها من كبسولات سيفدينير ( 600 ملغم/ يوم). معظم الآثار الجانبية كانت<br />معتدلة وتزول تلقائياً. لم يتم تسجيل أي حالات وفاة أو عجز دائم لها علاقة بسيفدينير. توقف بعض المرضى عن تناول هذا الدواء نتيجة لحصول<br />آثار جانبية اعتقد أنها مرتبطة باستعمال سيفدينير. تم التوقف عن تناول العلاج بشكل رئيسي نتيجة لحصول اضطرابات معدية معوية، عادة إسهال<br />أو شعور بالغثيان. توقف عدد قليل من المرضى عن تناول العلاج نتيجة لحدوث طفح اعتقد أن له علاقة بتناول سيفدينير.<br />الآثار الجانبية التالية يعتقد بأن لها علاقة بتناول كبسولات سيفدينير في الدراسات السريرية متعددة الجرعة:<br /><strong>الآثار الجانبية المرتبطة بتناول كبسولات سيفدينير للبالغين و المراهقين</strong><br /><strong>احتمالية حدوثها &lt; % 1:</strong> إسهال، داء المبيضات المهبلي، شعور بالغثيان، صداع، ألم في البطن، التهاب المهبل.<br /><strong>احتمالية الحدوث &gt; % 1 لكن &lt; % 0.1</strong> : طفح جلدي، عسر الهضم، انتفاخ البطن، قيء، تغير في طبيعة البراز، فقدان الشهية، إمساك، شعور<br />بالدوار، جفاف الفم، وهن، أرق، خروج سيلان أبيض اللون من المهبل، داء المبيضات، حكة، شعور بالنعاس.<br />تم ملاحظة تغيرات في القيم المخبرية التالية، بغض النظر عن علاقتها بالعلاج بسيفدينير خلال التجارب السريرية:<br />تغيرات في القيم المخبرية تم ملاحظتها عند العلاج بكبسولات سيفدينير عند البالغين و المراهقين<br />احتمالية حدوثها &lt; % 1: ارتفاع مستوى الخلايا البيضاء في البول، ارتفاع مستوى البروتين في البول، ارتفاع مستوى جاما-جلوتاميل<br />ترانزفيريز، ارتفاع مستوى الخلايا الليمفاوية، انخفاض مستوى الخلايا الليمفاوية، ارتفاع مستوى بيلة دموية مجهرية.<br />احتمالية الحدوث &gt; % 1 لكن &lt; % 0.1 : ارتفاع مستوى الجلوكوز، ارتفاع مستوى الجلوكوز في البول، ارتفاع عدد خلايا الدم البيضاء، انخفاض<br />عدد خلايا الدم البيضاء، ارتفاع مستوى ألانين أمينوترانزفيريز، كثرة الحمضات، ارتفاع الثقل النوعي للبول، انخفاض الثقل النوعي للبول،<br />انخفاض مستوى البيكربونات، ارتفاع مستوى الفسفور، انخفاض مستوى الفسفور، ارتفاع مستوى أسبارتيت أمينوترانزفيريز، ارتفاع مستوى<br />ألكالاين فوسفاتيز، ارتفاع مستوى نيتروجين يوريا الدم، انخفاض مستوى الهيموغلوبين، ارتفاع مستوى بولي مورفونيوكليار العدلات، انخفاض<br />مستوى بولي مورفونيوكليار العدلات، ارتفاع مستوى بيليروبين، ارتفاع مستوى ديهيدروجينيز لاكتيت، زيادة عدد الصفيحات، ارتفاع مستوى<br />البوتاسيوم، ارتفاع مستوى درجة حموضة البول.<br /><strong>سيفدينير معلق للشرب (المرضى الأطفال)</strong><br />في التجارب السريرية، تم علاج الأطفال بالجرعة الموصى بها من معلق سيفدينير ) 14 ملغم/كغم(. معظم الآثار الجانبية كانت معتدلة وتزول<br />تلقائياً. لم يتم تسجيل أي حالات وفاة أو عجز دائم لها علاقة بسيفدينير. توقف بعض المرضى عن تناول هذا الدواء نتيجة لحصول آثار جانبية اعتقد<br />أنها مرتبطة باستعمال سيفدينير. تم التوقف عن تناول العلاج بشكل رئيسي نتيجة لحصول اضطرابات معدية معوية، عادة إسهال. وتوقف عدد قليل<br />من المرضى عن تناول العلاج نتيجة لحدوث طفح له علاقة بتناول سيفدينير.<br /><strong>الآثار الجانبية المرتبطة بتناول معلق سيفدينير للأطفال</strong><br /><strong>احتمالية حدوثها &lt; % 1</strong>: إسهال، طفح، قيء.<br /><strong>احتمالية الحدوث &gt; % 1 لكن &lt; % 0.1 </strong>: داء المبيضات الجلدي، ألم في البطن، قلة الكريات البيض&dagger;، داء المبيضات المهبلي، التهاب المهبل،<br />تغير في طبيعة البراز، عسر الهضم، فرط النشاط الحركي، ارتفاع مستوى أسبارتيت أمينوترانزفيريز، طفح بقعي حطاطي، شعور بالغثيان.<br />&dagger; تم تسجيل تغيرات القيم المخبرية في بعض الأحيان كآثار جانبية.<br />ملاحظة: معدلات حدوث الإسهال والطفح كانت أكبر عند الأطفال الأصغر سنا.<br /><strong>إذا كان أي من الآثار الجانبية جدية أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول الأطفال و نظرهم.<br />لا تستخدم كبسولات أو معلق <strong>ديناسيف</strong><strong>&reg;</strong> بعد تاريخ انتهاء الصلاحية المذكورعلى الملصق و العلبة الخارجية.&nbsp;&nbsp;<br />تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.<br /><strong>ديناسيف</strong><strong>&reg;&nbsp;</strong>كبسولات و معلق للشرب: يحفظ بدرجة حرارة دون 30 &deg;م.&nbsp;<br /><strong>يستعمل المعلق خلال 14 يوما من تحضيره</strong><strong>.</strong><br />يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم<br />تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي سيفدينير.<br />المكونات الأخرى في <strong>الكبسولات </strong>هي ميكروكريستالين سيليلوز، صوديوم لوريل سلفات، كروسكارميلوز صوديوم، ستيرات المغنيسيوم.<br />المكونات الأخرى <strong>في معلق الشرب</strong> هي سكروز، ميثيل بارابين، صمغ زانثان، ميكروكريستالين سيليلوز و كاربوكسي ميثيل سيليلوز صوديوم،<br />رقم 40 ، بولي سوربيت 20 ، زيت السيميثيكون، ثاني أكسيد السيليكون الغروي، FD&amp;C حمض السيتريك، مسحوق نكهة الفواكة، لون أحمر<br />أيزوبروبانول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ديناسيف</strong><strong>&reg;&nbsp;&nbsp;300 </strong><strong>ملغم كبسولات&nbsp;</strong><br />وجسم غير شفاف ذو لون أحمر مطبوع عليه باللون ،MD كبسولات جيلاتينية ذات غطاء غير شفاف ذو لون أسود مطبوع عليه باللون الأبيض<br />حجم صفر، معدة للاستخدام عن طريق الفم. ،Denacif الأبيض 300<br /><strong>حجم العبوة</strong><strong>:</strong><br />10 كبسولات معبأة في عبوة متعددة الإيثيلين عالية الكثافة.<br /><strong>ديناسيف</strong><strong>&reg;&nbsp;</strong><strong>مسحوق لتحضير معلق للشرب</strong>&nbsp;<br />المسحوق قبل التحضير: حبيبات ذات لون مشمشي إلى وردي فاتح بنكهة توتي فروتي.<br />المسحوق بعد التحضير: معلق وردي اللون بنكهة توتي فروتي.<br />حجم العبوة:<br />50 مل و 100 مل.<br /><strong>كيفية تحضير المعلق</strong><strong>:</strong><br />إقلب القارورة لكي تحرك المسحوق داخلها، ثم أضف الماء المغلي والمبرد على دفعتين حتى العلامة المبينة على القارورة، ثم خض القارورة<br />جيداَ حتى يتم الحصول على معلق متجانس.<br /><strong>يستعمل المعلق خلال 14 يوما من تحضيره</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>تصنيع: الشركة الدولية للدواء - الأردن</strong><br /><strong>تعبئة: شركة مدينة الدواء للصناعات الدوائية - الممكلة العربية السعودية</strong><br /><strong>مالك رخصة التسويق: مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية</strong><br />هاتف: 00966920003288<br />فاكس: 00966126358138<br />جوال: 00966555786968<br />ص.ب: 42512 - جدة 21551<br />MD.admin@Axantia.com : بريد الكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Denacif® 300 mg Capsules. 
Cefdinir 300 mg Capsules.

Denacif® Powder for Oral Suspension. 
Cefdinir  125mg/5ml Powder for Oral Suspension.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Denacif® 300 mg Capsules: Each capsule contains 300 mg cefdinir.
Denacif® Powder for Oral Suspension: each 5 ml after reconstituted contains 125mg cefdinir. For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Denacif® Capsules.
Denacif® Powder for Oral Suspension.

Denacif® 300 mg Capsules
Hard gelatin capsule with black opaque cap printed in white color with MD, Red opaque body printed in white color with Denacif 300, size zero, intended for oral use.
Pack size:
10 capsules in HDPE bottle.

Denacif® Powder for Oral Suspension
Dry state: peach to light pink granules with tutti fruity flavor Reconstituted powder: pink suspension with tutti fruity flavor.  
Pack size:
50 ml and 100 ml.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p><p dir="ltr"><strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;</strong>is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.</p><p dir="ltr">Adults and Adolescents Community-Acquired Pneumonia</p><p dir="ltr">Caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Haemophilus parainfluenzae (including&nbsp;&nbsp;&nbsp;&nbsp; &beta;-lactamase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; producing&nbsp;&nbsp;&nbsp;&nbsp; strains), Streptococcus pneumonia</p><p dir="ltr">&nbsp;</p><p dir="ltr">(penicillin-susceptible&nbsp;&nbsp;&nbsp;&nbsp; strains&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; only),&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and Moraxella catarrhalis (including&nbsp;&nbsp;&nbsp;&nbsp; &beta;-lactamase producing strains).</p><p dir="ltr">Acute Exacerbations of Chronic Bronchitis</p><p dir="ltr">Caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Haemophilus parainfluenzae (including&nbsp;&nbsp;&nbsp;&nbsp; &beta;-lactamase&nbsp;&nbsp;&nbsp;&nbsp; producing&nbsp;&nbsp;&nbsp;&nbsp; strains), Streptococcus pneumonia (penicillin-susceptible&nbsp;&nbsp;&nbsp;&nbsp; strains&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; only),&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and Moraxella catarrhalis (including&nbsp;&nbsp;&nbsp;&nbsp; &beta;-lactamase producing strains).</p><p dir="ltr">Acute Maxillary Sinusitis</p><p dir="ltr">Caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;- lactamase producing strains).</p><p dir="ltr">NOTE: For information on use in pediatric patients.</p><p dir="ltr">Pharyngitis/Tonsillitis</p><p dir="ltr">Caused by Streptococcus pyogenes .</p><p dir="ltr">NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.</p><p dir="ltr">Uncomplicated Skin and Skin Structure Infections</p><p dir="ltr">caused&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by Staphylococcus aureus (including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &beta;-lactamase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; producing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strains) and Streptococcus pyogenes.</p><p dir="ltr">Pediatric Patients</p><p dir="ltr"><strong>Acute</strong><strong> </strong><strong>Bacterial</strong><strong> </strong><strong>Otitis Media</strong></p><p dir="ltr">Caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;- lactamase producing strains).</p><p dir="ltr">Pharyngitis/Tonsillitis</p><p dir="ltr">Caused by Streptococcus pyogenes (see CLINICAL STUDIES).</p><p dir="ltr"><strong>NOTE: </strong>Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.</p><p dir="ltr">Uncomplicated Skin and Skin Structure Infections</p><p dir="ltr">Caused&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by Staphylococcus aureus (including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &beta;-lactamase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; producing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strains) and Streptococcus pyogenes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">(See INDICATIONS AND USAGE for Indicated Pathogens)</p><p dir="ltr"><strong>Adults:</strong></p><p dir="ltr">The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily</p><p dir="ltr">dosing for 10 days is as effective as b.i.d. dosing. Once-daily dosing has not been studied in pneumonia or skin infections; therefore, <strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;</strong>capsules should be administered twice daily in these infections. <strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;</strong>capsules may be taken without regard to meals.</p><p dir="ltr"><strong>Adults and Adolescents (Age 13 Years and Older)</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Type of Infection</strong></p></td><td><p><strong>Dosage</strong></p></td><td><p><strong>Duration</strong></p></td></tr><tr><td><p>Community-Acquired Pneumonia</p></td><td><p>300 mg q12h</p></td><td><p>10 days</p></td></tr><tr><td><p>Acute Exacerbations of Chronic Bronchitis</p></td><td><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Acute Maxillary Sinusitis</p></td><td><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Pharyngitis/Tonsillitis</p></td><td><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Uncomplicated Skin and Skin Structure Infections</p></td><td><p>300 mg q12h</p></td><td><p>10 days</p></td></tr></tbody></table><p dir="ltr"><strong>Children:</strong></p><p dir="ltr">The recommended dosage and duration of treatment for infections in pediatric patients are described in the following chart; the total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in skin infections; therefore, <strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;</strong>for oral suspension should be administered twice daily in this infection. <strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;</strong>for oral suspension may be administered without regard to meals.</p><p dir="ltr"><strong>Pediatric Patients (Age 6 Months Through 12 Years)</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Type of Infection</strong></p></td><td><p><strong>Dosage</strong></p></td><td><p><strong>Duration</strong></p></td></tr><tr><td><p>Acute Bacterial Otitis Media</p></td><td><p>7 mg/kg q12h</p><p>or</p><p>14 mg/kg q24h</p></td><td><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Acute Maxillary Sinusitis</p></td><td><p>7 mg/kg q12h</p><p>or</p><p>14 mg/kg q24h</p></td><td><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Pharyngitis/Tonsillitis</p></td><td><p>7 mg/kg q12h</p><p>or</p><p>14 mg/kg q24h</p></td><td><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Uncomplicated Skin and Skin&nbsp;Structure Infections</p></td><td><p>7 mg/kg q12h</p></td><td><p>10 days</p></td></tr></tbody></table><p dir="ltr"><strong>Pediatric</strong><strong> patients who weigh &ge;43 kg should receive the maximum daily dose of 600 mg.</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Weight</strong></p></td><td><p><strong>125 mg/5 mL</strong></p></td><td><p><strong>250 mg/5 mL</strong></p></td></tr><tr><td><p>9 kg/20 lbs</p></td><td><p>2.5 mL q12h or 5 mL q24h</p></td><td><p>Use 125 mg/5 mL product</p></td></tr><tr><td><p>18 kg/40 lbs</p></td><td><p>5 mL q12h or 10 mL q24h</p></td><td><p>2.5 mL q12h or 5 mL q24h</p></td></tr><tr><td><p>27 kg/60 lbs</p></td><td><p>7.5 mL q12h or 15 mL q24h</p></td><td><p>3.75 mL q12h or 7.5 mL q24h</p></td></tr><tr><td><p>36 kg/80 lbs</p></td><td><p>10 mL q12h or 20 mL q24h</p></td><td><p>5 mL q12h or 10 mL q24h</p></td></tr><tr><td><p>&ge;43 kg*/95 lbs</p></td><td><p>12 mL q12h or 24 mL q24h</p></td><td><p>6 mL q12h or 12 mL q24h</p></td></tr></tbody></table><p dir="ltr">*Pediatric patients who weigh &ge; 4 3 kg should receive the maximum daily dose of 600 mg.</p><p dir="ltr"><strong>Patients with Renal Insufficiency</strong></p><p dir="ltr">For adult patients with creatinine clearance &lt;30 mL/min, the dose of <strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;</strong>should be 300 mg given once daily.</p><p dir="ltr">Creatinine clearance is difficult to measure in outpatients. However, the following formula may be used to estimate creatinine clearance (CLcr) in adult patients. For estimates to be valid, serum creatinine levels should reflect steady-state levels of renal function.</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2"><p>Males:</p></td><td rowspan="2"><p>CLcr =</p></td><td><p>(weight) (140 &ndash; age)</p></td></tr><tr><td><p>(72) (serum creatinine)</p></td></tr><tr><td><p>Females:</p></td><td><p>CLcr =</p></td><td><p>0.85 x above value</p></td></tr><tr><td colspan="3"><p>Where creatinine clearance is in mL/min, age is in years, weight is in kilograms, and serum creatinine is in mg/dL.(3)</p></td></tr></tbody></table><p dir="ltr"><strong>The following formula may be used to estimate creatinine clearance in pediatric patients:</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2"><p>CLcr = K x</p></td><td><p>body length or height</p></td></tr><tr><td><p>serum creatinine</p></td></tr><tr><td colspan="2"><p>Where K=0.55 for pediatric patients older than 1 year (4) and 0.45 for infants (up to 1 year). (5)</p></td></tr></tbody></table><p dir="ltr">In the above equation, creatinine clearance is in mL/min/1.73 m2, body length or height is in centimeters, and serum creatinine is in mg/dL.</p><p dir="ltr">For &nbsp;pediatric &nbsp;patients &nbsp;with &nbsp;a &nbsp;creatinine &nbsp;clearance &nbsp;of &nbsp;&lt;30 &nbsp;mL/min/1.73 &nbsp;m2, &nbsp;the &nbsp;dose &nbsp;of</p><p dir="ltr"><strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;</strong>should be 7 mg/kg (up to 300 mg) given once daily.</p><p dir="ltr">Patients on Hemodialysis</p><p dir="ltr">Hemodialysis removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day. At the conclusion of each hemodialysis session, 300 mg (or 7 mg/kg) should be given. Subsequent doses (300 mg or 7 mg/kg) are then administered every other day.</p><p dir="ltr">Method of the reconstitution for Denacif&reg;</p><p dir="ltr">Invert the bottle and shake powder loose.</p><p dir="ltr">Add boiled and cooled water in two portions up to the mark indicated on the bottle, shake after each addition until a homogeneous suspension is achieved.</p><p dir="ltr">After reconstitution, the suspension should be used within 14 days.<strong>&nbsp;</strong></p><p dir="ltr"><strong>CLINICAL</strong><strong> </strong><strong>STUDIES</strong></p><p dir="ltr"><strong>Community-Acquired</strong><strong> </strong><strong>Bacterial</strong><strong> </strong><strong>Pneumonia</strong></p><p dir="ltr">In a controlled, double-blind study in adults and adolescents conducted in the U.S., cefdinir</p><p dir="ltr">b.i.d. was compared with cefaclor 500 mg t.i.d. Using strict evaluability and microbiologic/clinical response criteria 6 to 14 days post therapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:</p><p dir="ltr"><strong>&nbsp;U.S. Community-Acquired Pneumonia Study Cefdinir vs Cefaclor</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Cefdinir b.i.d.</strong></p></td><td><p><strong>Cefaclor t.i.d</strong></p></td><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Outcome</strong></p></td></tr><tr><td><p><strong>Clinical Cure Rates</strong></p></td><td><p>150/187 (80%)</p></td><td><p>147/186 (79%)</p></td><td><p>Cefdinir equivalent to control</p></td></tr><tr><td colspan="3"><p><strong>Eradication Rates</strong></p></td><td rowspan="6"><p>Cefdinir equivalent to control</p></td></tr><tr><td><p>Overall</p></td><td><p>177/195 (91%)</p></td><td><p>184/200 (92%)</p></td></tr><tr><td><p>S. pneumoniae</p></td><td><p>31/31 (100%)</p></td><td><p>35/35 (100%)</p></td></tr><tr><td><p>H. influenzae</p></td><td><p>55/65 (85%)</p></td><td><p>60/72 (83%)</p></td></tr><tr><td><p>M. catarrhalis</p></td><td><p>10/10 (100%)</p></td><td><p>11/11 (100%)</p></td></tr><tr><td><p>H. parainfluenzae</p></td><td><p>81/89 (91%)</p></td><td><p>78/82 (95%)</p></td></tr></tbody></table><p dir="ltr">In a second controlled, investigator-blind study in adults and adolescents conducted primarily in Europe, cefdinir b.i.d. was compared with amoxicillin/clavulanate 500/125 mg t.i.d. Using strict evaluability and clinical response criteria 6 to 14 days post therapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:</p><p dir="ltr"><strong>European Community-Acquired Pneumonia Study Cefdinir vs Amoxicillin/Clavulanate</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td>&nbsp;</td><td><p><strong>Cefdinir b.i.d.</strong></p></td><td><p><strong>Amoxicillin/ Clavulanate t.i.d.</strong></p></td><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Outcome</strong></p></td></tr><tr><td><p><strong>Clinical Cure Rates</strong></p></td><td><p>83/104 (80%)</p></td><td><p>86/97 (89%)</p></td><td><p>Cefdinir not equivalent to control</p></td></tr><tr><td colspan="3"><p><strong>Eradication Rates</strong></p></td><td rowspan="6"><p>Cefdinir equivalent to control</p></td></tr><tr><td><p>Overall</p></td><td><p>85/96 (89%)</p></td><td><p>84/90 (93%)</p></td></tr><tr><td><p>S. pneumoniae</p></td><td><p>31/31 (100%)</p></td><td><p>43/44 (98%)</p></td></tr><tr><td><p>H. influenzae</p></td><td><p>55/65 (85%)</p></td><td><p>21/26 (81%)</p></td></tr><tr><td><p>M. catarrhalis</p></td><td><p>10/10 (100%)</p></td><td><p>8/8 (100%)</p></td></tr><tr><td><p>H.parainfluenzae</p></td><td><p>81/89 (91%)</p></td><td><p>12/12 (100%)</p></td></tr></tbody></table><p dir="ltr"><strong>Streptococcal</strong><strong> </strong><strong>Pharyngitis</strong><strong> </strong><strong>/Tonsillitis</strong></p><p dir="ltr">In four controlled studies conducted in the United States, cefdinir was compared with 10 days of penicillin in adult, adolescent, and pediatric patients. Two studies (one in adults and adolescents, the other in pediatric patients) compared 10 days of cefdinir q.d. or b.i.d. to penicillin 250 mg or 10 mg/kg q.i.d. Using strict evaluability and microbiologic/clinical response criteria 5 to 10 days post therapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:</p><p dir="ltr"><strong>Pharyngitis /Tonsillitis Studies Cefdinir (10 days ) vs Penicillin (10 days )</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Study</strong></p></td><td><p><strong>Efficacy</strong></p><p><strong>Parameter</strong></p></td><td><p><strong>Cefdinir</strong></p><p><strong>q.d.</strong></p></td><td><p><strong>Cefdinir</strong></p><p><strong>b.i.d.</strong></p></td><td><p><strong>Penicillin</strong></p><p><strong>q.i.d.</strong></p></td><td><p><strong>Outcome</strong></p></td></tr><tr><td rowspan="2"><p>Adults/</p><p>Adolescents</p></td><td rowspan="2"><p>Eradication</p><p>of S. pyogenes</p><p>Clinical Cure Rates</p></td><td><p>192/210</p><p>(91%)</p></td><td><p>199/217</p><p>(92%)</p></td><td><p>181/217</p><p>(83%)</p></td><td><p>Cefdinir</p><p>superior to control</p></td></tr><tr><td><p>199/210</p><p>(95%)</p></td><td><p>209/217</p><p>(96%)</p></td><td><p>193/217</p><p>(89%)</p></td><td><p>Cefdinir</p><p>superior to control</p></td></tr><tr><td rowspan="2"><p>Pediatric</p><p>Patients</p></td><td rowspan="2"><p>Eradication</p><p>of S.pyogenes</p><p>Clinical Cure Rates</p></td><td><p>215/228</p><p>(94%)</p></td><td><p>214/227</p><p>(94%)</p></td><td><p>159/227</p><p>(70%)</p></td><td><p>Cefdinir</p><p>superior to control</p></td></tr><tr><td><p>222/228</p><p>(97%)</p></td><td><p>218/227</p><p>(96%)</p></td><td><p>196/227</p><p>(86%)</p></td><td><p>Cefdinir</p><p>superior to control</p></td></tr></tbody></table><p dir="ltr">Two studies (one in adults and adolescents, the other in pediatric patients) compared 5 days of cefdinir b.i.d. to 10 days of penicillin 250 mg or 10 mg/kg q.i.d. Using strict evaluability and microbiologic/clinical response criteria 4 to 10 days post therapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:</p><p dir="ltr"><strong>Pharyngitis /Tonsillitis Studies Cefdinir (5 days ) vs Penicillin (10 days )</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Study</strong></p></td><td><p><strong>Efficacy</strong></p><p><strong>Parameter</strong></p></td><td><p><strong>Cefdinir</strong></p><p><strong>b.i.d.</strong></p></td><td><p><strong>Penicillin</strong></p><p><strong>q.i.d.</strong></p></td><td><p><strong>Outcome</strong></p></td></tr><tr><td rowspan="2"><p>Adults/</p><p>Adolescents</p></td><td rowspan="2"><p>Eradication</p><p>of S. pyogenes</p><p>Clinical Cure Rates</p></td><td><p>176/214 (82%)</p></td><td><p>176/214 (82%)</p></td><td><p>Cefdinir</p><p>superior to control</p></td></tr><tr><td><p>194/218 (89%)</p></td><td><p>181/214 (85%)</p></td><td><p>Cefdinir</p><p>superior to control</p></td></tr><tr><td rowspan="2"><p>Pediatric</p><p>Patients</p></td><td rowspan="2"><p>Eradication</p><p>of S.pyogenes</p><p>Clinical Cure Rates</p></td><td><p>176/196 (90%)</p></td><td><p>135/193 (70%)</p></td><td><p>Cefdinir</p><p>superior to control</p></td></tr><tr><td><p>179/196 (91%)</p></td><td><p>173/193 (90%)</p></td><td><p>Cefdinir</p><p>superior to control</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
-	Hypersensitivity to any of the excipients listed in section 6.1.
-	History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of betalactam antibacterial agent (penicillins, monobactams and carbapenems).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>WARNINGS</strong></p><p dir="ltr">BEFORE THERAPY WITH CEFDINIR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFDINIR, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFDINIR IS TO BE GIVEN TO PENICILLIN- SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS- HYPERSENSITIVITY AMONG &beta;-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFDINIR OCCURS, THE DRUG SHOULD BE DISCONTINUED. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</p><p dir="ltr">Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefdinir, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.</p><p dir="ltr">C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p><p dir="ltr">If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.</p><p dir="ltr">Interference with diagnostic tests</p><p dir="ltr">The development of a positive Coomb&#39;s Test associated with the use of cefdinir may interfere with cross matching of blood (see section 4.8).As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefdinir.</p><p dir="ltr"><strong>PRECAUTIONS</strong></p><p dir="ltr"><strong>General</strong></p><p dir="ltr">Prescribing cefdinir in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p><p dir="ltr">As with other broad-spectrum antibiotics, prolonged treatment may result in the possible emergence and&nbsp; overgrowth of resistant&nbsp; organisms.&nbsp; Careful observation&nbsp; of the&nbsp; patient is essential. If superinfection occurs during therapy, appropriate alternative therapy should be administered.</p><p dir="ltr">Cefdinir, as with other broad-spectrum antimicrobials (antibiotics), should be prescribed with caution in individuals with a history of colitis.</p><p dir="ltr">In patients with transient or persistent renal insufficiency (creatinine clearance &lt; 30 mL/min), the total daily dose of cefdinir should be reduced because high and prolonged plasma concentrations of cefdinir can result following recommended doses</p><p dir="ltr"><strong>Excipients:</strong></p><p dir="ltr"><strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;</strong>contains sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">(aluminum - or magnesium - containing): Concomitant administration of 300 mg cefdinir capsules with 30 mL Maalox&reg;&nbsp;TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. Time to reach Cmax is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the antacid.</p><p dir="ltr"><strong>Probenecid</strong></p><p dir="ltr">As with other &beta;-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in AUC, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination t&frac12;.</p><p dir="ltr"><strong>Iron Supplements and Foods Fortified With Iron</strong></p><p dir="ltr">Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement.</p><p dir="ltr">The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.</p><p dir="ltr">Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics. Therefore, cefdinir for oral suspension can be administered with iron-fortified infant formula.</p><p dir="ltr">There have been reports of reddish stools in patients receiving cefdinir. In many cases, patients were also receiving iron-containing products. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.</p><p dir="ltr"><strong>Drug/Laboratory Test Interactions</strong></p><p dir="ltr">A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false- positive reaction for glucose in urine using Clinitest&reg;, Benedict&rsquo;s solution, or Fehling&#39;s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix&reg;&nbsp;or Tes-Tape&reg;) be used. Cephalosporins are known to occasionally induce a positive direct Coombs&rsquo; test.</p><p dir="ltr"><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p dir="ltr">The carcinogenic potential of cefdinir has not been evaluated. No mutagenic effects were seen in the bacterial reverse mutation assay (Ames) or point mutation assay at the hypoxanthine-guanine phosphoribosyltransferase locus (HGPRT) in V79 Chinese hamster lung cells. No clastogenic effects were observed in vitro in the structural chromosome aberration assay in V79 Chinese hamster lung cells or in vivo in the micronucleus assay in mouse bone marrow. In rats, fertility and reproductive performance were not affected by cefdinir at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m2/day).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Teratogenic</strong><strong> </strong><strong>Effects</strong><strong> </strong></p><p dir="ltr"><strong>Pregnancy</strong><strong> </strong><strong>Category B</strong></p><p dir="ltr">Cefdinir was not teratogenic in rats at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m2/day) or in rabbits at oral doses up to 10 mg/kg/day (0.7 times the human dose based on mg/kg/day, 0.23 times based on mg/m2/day). Maternal toxicity (decreased body weight gain) was observed in rabbits at the maximum tolerated dose of 10 mg/kg/day without adverse effects on offspring. Decreased body weight occurred in rat fetuses at &ge;100 mg/kg/day, and in rat offspring at &ge;32 mg/kg/day. No effects were observed on maternal reproductive parameters or offspring survival, development, behavior, or reproductive function.</p><p dir="ltr">There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p><p dir="ltr"><strong>Labor and Delivery</strong></p><p dir="ltr">Cefdinir has not been studied for use during labor and delivery.</p><p dir="ltr"><strong>Nursing Mothers</strong></p><p dir="ltr">Following administration of single 600 mg doses, cefdinir was not detected in human breast milk.</p><p dir="ltr"><strong>Pediatric Use</strong></p><p dir="ltr">Safety and efficacy in&nbsp; neonates and infants less than 6 months of age have&nbsp; not been established. Use of cefdinir for the treatment of acute maxillary sinusitis in pediatric patients (age 6 months through 12 years) is supported by evidence from adequate and well-controlled</p><p dir="ltr">studies in adults and adolescents, the similar pathophysiology of acute sinusitis in adult and pediatric patients, and comparative pharmacokinetic data in the pediatric population.</p><p dir="ltr"><strong>Geriatric Use</strong></p><p dir="ltr">Efficacy is comparable in geriatric patients and younger adults. While cefdinir has been well- tolerated in all age groups, in clinical trials geriatric patients experienced a lower rate of adverse events, including diarrhea, than younger adults. Dose adjustment in elderly patients is not necessary unless renal function is markedly compromised</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No studies on the effects on the ability to drive and use machines have been performed. However, as this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Cefdinir</strong><strong> </strong><strong>Capsules</strong><strong> </strong><strong>(Adult</strong><strong> </strong><strong>and Adolescent Patients)</strong></p><p dir="ltr">In clinical trials, 5093 adult and adolescent patients (3841 U.S. and 1252 non-U.S.) were treated with the recommended dose of cefdinir capsules (600 mg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. One hundred forty-seven of 5093 (3%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea or nausea. Nineteen of 5093 (0.4%) patients were discontinued due to rash thought related to cefdinir administration.</p><p dir="ltr">In the U.S., the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir capsules in multiple-dose clinical trials (N=3841 cefdinir-treated patients):</p><p dir="ltr"><strong>Adverse Events Associated with Cefdinir Capsules U.S. Trials in Adult and Adolescent Patients (N=3841)*</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p>Incidence &ge; 1%</p></td><td><p>Diarrhea</p></td><td><p>15%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vaginal moniliasis</p></td><td><p>4% of women</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Nausea</p></td><td><p>3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Headache</p></td><td><p>2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Abdominal pain</p></td><td><p>1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vaginitis</p></td><td><p>1% of women</p></td></tr><tr><td><p>Incidence &lt; 1%</p><p>but &gt; 0.1%</p></td><td><p>Rash</p></td><td><p>0.9%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dyspepsia</p></td><td><p>0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Flatulence</p></td><td><p>0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vomiting</p></td><td><p>0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Abnormal stools</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Anorexia</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Constipation</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dizziness</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dry mouth</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Asthenia</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Insomnia</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Leukorrhea</p></td><td><p>0.2% of women</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Moniliasis</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pruritus</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Somnolence</p></td><td><p>0.2%</p></td></tr></tbody></table><p dir="ltr">* 1733 males, 2108 females</p><p dir="ltr">The &nbsp;following &nbsp;laboratory &nbsp;value &nbsp;changes &nbsp;of &nbsp;possible &nbsp;clinical &nbsp;significance, &nbsp;irrespective &nbsp;of relationship to therapy with cefdinir, were seen during clinical trials conducted in the U.S.:</p><p dir="ltr"><strong>Laboratory Value Changes Observed with Cefdinir Capsules U.S. Trials in Adult and </strong></p><p dir="ltr"><strong>Patients (N=3841)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" dir="ltr"><tbody><tr><td><p>Incidence &ge; 1%</p></td><td><p>&uarr;Urine leukocytes</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Urine protein</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Gamma-glutamyltransferase*</p></td><td><p>1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&darr;Lymphocytes, &uarr;Lymphocytes</p></td><td><p>1%, 0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Microhematuria</p></td><td><p>1%</p></td></tr><tr><td><p>Incidence &lt; 1%</p><p>but &gt; 0.1%</p></td><td><p>&uarr;Glucose*</p></td><td><p>0.9%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Urine glucose</p></td><td><p>0.9%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;White blood cells, &darr;White blood cells</p></td><td><p>0.9%, 0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Alanine aminotransferase (ALT)</p></td><td><p>0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Eosinophils</p></td><td><p>0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Urine specific gravity, &darr;Urine specific gravity*</p></td><td><p>0.6%, 0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&darr;Bicarbonate*</p></td><td><p>0.6%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Phosphorus, &darr;Phosphorus*</p></td><td><p>0.6%, 0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Aspartate aminotransferase (AST)</p></td><td><p>0.4%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Alkaline phosphatase</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Blood urea nitrogen (BUN)</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&darr;Hemoglobin</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Polymorphonuclear neutrophils (PMNs), &darr;PMNs</p></td><td><p>0.3%, 0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Bilirubin</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Lactate dehydrogenase*</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Platelets</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Potassium*</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Urine pH*</p></td><td><p>0.2%</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="ltr">*N &lt; 3841 for these parameters</p><p dir="ltr"><strong>Clinical Trials - Cefdinir for Oral Suspension (Pediatric Patients)</strong></p><p dir="ltr">In clinical trials, 2289 pediatric patients (1783 U.S. and 506 non-U.S.) were treated with the recommended dose of cefdinir suspension (14 mg/kg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. Forty of 2289 (2%) patients discontinued medication due to adverse events considered by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. Discontinuations were primarily for gastrointestinal disturbances, usually diarrhea. Five of 2289 (0.2%) patients were discontinued due to rash thought related to cefdinir administration.</p><p dir="ltr">In the U.S., the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir suspension in multiple-dose clinical trials (N=1783 cefdinir-treated patients):</p><p dir="ltr"><strong>ADVERSE EVENTS ASSOCIATED WITH CEFDINIR SUSPENSION U.S. TRIALS IN PEDIATRIC PATIENTS (N=1783)*</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p>Incidence &ge; 1%</p></td><td><p>Diarrhea</p></td><td><p>8%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Rash</p></td><td><p>3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vomiting</p></td><td><p>1%</p></td></tr><tr><td><p>Incidence &lt; 1%</p><p>but &gt; 0.1%</p></td><td><p>Cutaneous moniliasis</p></td><td><p>0.9%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Abdominal pain</p></td><td><p>0.8%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Leukopenia&dagger;</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vaginal moniliasis</p></td><td><p>0.3% of girls</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vaginitis</p></td><td><p>0.3% of girls</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Abnormal stools</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dyspepsia</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hyperkinesia</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Increased AST&dagger;</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Maculopapular rash</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Nausea</p></td><td><p>0.2%</p></td></tr></tbody></table><p dir="ltr">* 977 males, 806 females</p><p dir="ltr">&dagger; Laboratory changes were occasionally reported as adverse events.</p><p dir="ltr"><strong>NOTE:</strong><strong> </strong>In both cefdinir- and control-treated patients, rates of diarrhea and rash were higher in the youngest pediatric patients. The incidence of diarrhea in cefdinir-treated patients &le;2 years of age was 17% (95/557) compared with 4% (51/1226) in those &gt;2 years old. The incidence of rash (primarily diaper rash in the younger patients) was 8% (43/557) in patients &le;2 years of age compared with 1% (8/1226) in those &gt;2 years old.</p><p dir="ltr">The &nbsp;following &nbsp;laboratory &nbsp;value &nbsp;changes &nbsp;of &nbsp;possible &nbsp;clinical &nbsp;significance, &nbsp;irrespective &nbsp;of relationship to therapy with cefdinir, were seen during clinical trials conducted in the U.S.:</p><p dir="ltr"><strong>LABORATORY</strong><strong> </strong><strong>VALUE</strong><strong> </strong><strong>CHANGES</strong><strong> </strong><strong>OF POSSIBLE CLINICAL SIGNIFICANCE OBSERVED</strong>WITH <strong>CEFDINIR SUSPENSION U.S. TRIALS IN PEDIATRIC PATIENTS (N=1783)</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" dir="ltr"><tbody><tr><td><p>Incidence &ge; 1%</p></td><td><p>&uarr;Lymphocytes, &darr;Lymphocytes</p></td><td><p>2%, 0.8%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Alkaline phosphatase</p></td><td><p>1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&darr; Bicarbonate*</p></td><td><p>1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Eosinophils</p></td><td><p>1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Lactate dehydrogenase</p></td><td><p>1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Platelets</p></td><td><p>1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr; Polymorphonuclear neutrophils (PMNs), &darr;PMNs</p></td><td><p>1%, 1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Urine protein</p></td><td><p>1%</p></td></tr><tr><td><p>Incidence &lt;1% but &gt;0.1%</p></td><td><p>&uarr;Phosphorus, &darr;Phosphorus</p></td><td><p>0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Urine pH</p></td><td><p>0.8%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&darr;White blood cells, &uarr;White blood cells</p></td><td><p>0.7%, 0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&darr;Calcium*</p></td><td><p>0.5%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&darr; Hemoglobin</p></td><td><p>0.5%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Urine leukocytes</p></td><td><p>0.5%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Monocytes</p></td><td><p>0.4%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;AST</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Potassium*</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&uarr;Urine specific gravity, &darr;Urine specific gravity</p></td><td><p>0.3%, 0.1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&darr;Hematocrit*</p></td><td><p>0.2%</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>*</u>N=1387 for these parameters</p><p dir="ltr"><strong>Post-marketing Experience</strong></p><p dir="ltr">The &nbsp;following &nbsp;adverse &nbsp;experiences &nbsp;and &nbsp;altered &nbsp;laboratory &nbsp;tests, &nbsp;regardless &nbsp;of &nbsp;their relationship &nbsp;to &nbsp;cefdinir, &nbsp;have &nbsp;been &nbsp;reported &nbsp;during &nbsp;extensive &nbsp;postmarketing &nbsp;experience, beginning with approval in Japan in 1991: shock, anaphylaxis with rare cases of fatality, facial and laryngeal edema, feeling of suffocation, serum sickness-like reactions, conjunctivitis, stomatitis, &nbsp;Stevens-Johnson &nbsp;syndrome, &nbsp;toxic &nbsp;epidermal &nbsp;necrolysis, &nbsp;exfoliative &nbsp;dermatitis, erythema multiforme, erythema nodosum, acute &nbsp;hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice, increased amylase, acute enterocolitis, bloody diarrhea, hemorrhagic colitis, &nbsp;melena, &nbsp;pseudomembranous &nbsp;colitis, &nbsp;pancytopenia, &nbsp;granulocytopenia, &nbsp;leucopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, acute respiratory failure, &nbsp;asthmatic &nbsp;attack, &nbsp;drug-induced&nbsp;&nbsp;&nbsp; pneumonia, &nbsp;eosinophilic &nbsp;pneumonia, &nbsp;idiopathic interstitial pneumonia, fever, acute renal failure, nephropathy, bleeding tendency, coagulation disorder, disseminated intravascular coagulation, upper GI bleed, peptic ulcer, ileus, loss of consciousness, allergic vasculitis, possible cefdinir-diclofenac interaction, cardiac failure, chest pain, myocardial infarction, hypertension, involuntary movements, and rhabdomyolysis.</p><p dir="ltr"><strong>Cephalosporin Class Adverse Events</strong></p><p dir="ltr">The &nbsp;following &nbsp;adverse &nbsp;events &nbsp;and &nbsp;altered &nbsp;laboratory &nbsp;tests &nbsp;have &nbsp;been &nbsp;reported &nbsp;for cephalosporin-class antibiotics in general:</p><p dir="ltr">Allergic &nbsp;reactions, &nbsp;anaphylaxis, &nbsp;Stevens-Johnson &nbsp;syndrome, &nbsp;erythema &nbsp;multiforme, &nbsp;toxic epidermal &nbsp;necrolysis, &nbsp;renal &nbsp;dysfunction, &nbsp;toxic &nbsp;nephropathy, &nbsp;hepatic &nbsp;dysfunction &nbsp;including</p><p dir="ltr">cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, false-positive test for urinary glucose, neutropenia, pancytopenia, and agranulocytosis. Pseudomembranous colitis symptoms may begin during or after antibiotic treatment.</p><p dir="ltr">Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should&nbsp; be discontinued.&nbsp; Anticonvulsant therapy can&nbsp; be given&nbsp; if clinically indicated.</p><p dir="ltr"><strong>To report any side effect(s):</strong></p><p dir="ltr"><strong>&bull;Saudi Arabia:</strong></p><p dir="ltr">The National Pharmacovigilance and Drug Safety Center (NPC): Fax: +966-11-205-7662</p><p dir="ltr">Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p dir="ltr">Reporting hotline: 19999</p><p dir="ltr">E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p><p dir="ltr"><strong>&bull;Other GCC States:</strong></p><p dir="ltr">Please contact the relevant competent authority</p><p dir="ltr">To report any side effect(s):</p><p dir="ltr"><strong>&bull;Saudi Arabia:</strong></p><p dir="ltr">The National Pharmacovigilance and Drug Safety Center (NPC): Fax: +966-11-205-7662</p><p dir="ltr">Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p dir="ltr">Reporting hotline: 19999</p><p dir="ltr">E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p><p dir="ltr"><strong>&bull;Other GCC States:</strong></p><p dir="ltr">Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600 mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other &beta;-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis removes cefdinir from the body. This may be useful in the event of a serious toxic reaction from overdosage, particularly if renal function is compromised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Mechanism</strong><strong> </strong><strong>of Action:</strong></p><p dir="ltr">As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, &beta;-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.</p><p dir="ltr"><strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;&nbsp; &nbsp;</strong>contain &nbsp;the &nbsp;active &nbsp;ingredient &nbsp;cefdinir, &nbsp;an &nbsp;extended-spectrum, &nbsp;semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6&alpha;,7&beta; (Z)]]-7-[[(2-amino-4- thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid. Cefdinir is a white to slightly brownish-yellow solid. It is slightly soluble in dilute hydrochloric acid and sparingly soluble in 0.1 M pH 7.0 phosphate buffer. The empirical formula is C14H13N5O5S2 and the molecular weight is 395.42</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Absorption</strong></p><p dir="ltr"><strong>Oral Bioavailability</strong></p><p dir="ltr">Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Plasma cefdinir concentrations increase with dose, but the increases are less than dose-proportional from 300 mg (7 mg/kg) to 600 mg (14 mg/kg). Following administration of suspension to healthy adults, cefdinir bioavailability is 120% relative to&nbsp; capsules. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%. Cefdinir oral suspension of 250 mg/5 mL strength was shown to be bioequivalent to the 125 mg/5 mL strength in healthy adults under fasting conditions.</p><p dir="ltr"><strong>Effect of Food</strong></p><p dir="ltr">The Cmax and AUC of cefdinir from the capsules are reduced by 16% and 10%, respectively, when given with a high-fat meal. In adults given the 250 mg/5 mL oral suspension with a high- fat meal, the Cmaxand AUC of cefdinir are reduced by 44% and 33%, respectively. The magnitude of these reductions is not likely to be clinically significant because the safety and efficacy studies of oral suspension in pediatric patients were conducted without regard to food intake. Therefore, cefdinir may be taken without regard to food.</p><p dir="ltr">Cefdinir Capsules: Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 300 and 600 mg oral doses of cefdinir to adult subjects are presented in the following table:</p><p dir="ltr"><strong>Mean (&plusmn;SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following Administration of Capsules to Adult Subjects</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p>Dose</p></td><td><p>Cmax</p><p>(mcg/mL)</p></td><td><p>Tmax</p><p>(hr)</p></td><td><p>AUC</p><p>(mcg&bull;hr/mL)</p></td></tr><tr><td><p>300 mg</p></td><td><p>1.6</p><p>(0.55)</p></td><td><p>2.9</p><p>(0.89)</p></td><td><p>7.05</p><p>(2.17)</p></td></tr><tr><td><p>600 mg</p></td><td><p>2.87</p><p>(1.01)</p></td><td><p>3</p><p>(0.66)</p></td><td><p>11.1</p><p>(3.87)</p></td></tr></tbody></table><p dir="ltr"><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:46.55pt;margin-top:-2.35pt;width:494.15pt;height:6.05pt;z-index:-58168;
 mso-position-horizontal-relative:page' coordorigin="931,-47" coordsize="9883,121">
 <v:group id="_x0000_s1027" style='position:absolute;left:931;top:-47;width:9883;
  height:120' coordorigin="931,-47" coordsize="9883,120">
  <v:shape id="_x0000_s1028" style='position:absolute;left:931;top:-47;width:9883;
   height:120' coordorigin="931,-47" coordsize="9883,120" path="m931,73r9883,l10814,-47r-9883,l931,73xe"
   fillcolor="#eef9ff" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1029" style='position:absolute;
  left:934;top:-40;width:9881;height:53' coordorigin="934,-40" coordsize="9881,53">
  <v:shape id="_x0000_s1030" style='position:absolute;left:934;top:-40;width:9881;
   height:53' coordorigin="934,-40" coordsize="9881,53" path="m934,12r9880,l10814,-40r-9880,l934,12xe"
   fillcolor="#eef9ff" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1031" style='position:absolute;
  left:934;top:12;width:9878;height:62' coordorigin="934,12" coordsize="9878,62">
  <v:shape id="_x0000_s1032" style='position:absolute;left:934;top:12;width:9878;
   height:62' coordorigin="934,12" coordsize="9878,62" path="m934,74r9878,l10812,12,934,12r,62xe"
   fillcolor="#eef9ff" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="659" height="8" src="file:///C:/Users/Basmah.alrashdi/AppData/Local/Packages/oice_16_974fa576_32c1d314_3824/AC/Temp/msohtmlclip1/01/clip_image001.gif" />Cefdinir Suspension: Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 7 and 14 mg/kg oral doses of cefdinir to pediatric subjects (age 6 months to 12 years) are presented in the following table:</p><p dir="ltr"><strong>Mean (&plusmn;SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following Administration of Suspension to Pediatric Subjects</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p>Dose</p></td><td><p>Cmax</p><p>(mcg/mL)</p></td><td><p>Tmax</p><p>(hr)</p></td><td><p>AUC</p><p>(mcg&bull;hr/mL)</p></td></tr><tr><td><p>7 mg/kg</p></td><td><p>2.3</p><p>(0.65)</p></td><td><p>2.2</p><p>(0.6)</p></td><td><p>8.31</p><p>(2.5)</p></td></tr><tr><td><p>14 mg/kg</p></td><td><p>3.86</p><p>(0.62)</p></td><td><p>1.8</p><p>(0.4)</p></td><td><p>13.4</p><p>(2.64)</p></td></tr></tbody></table><p><strong><em>Multiple</em></strong><strong><em> </em></strong><strong><em>Dosing</em></strong></p><p dir="ltr">Cefdinir does not accumulate in plasma following once- or twice-daily administration to subjects with normal renal function.</p><p dir="ltr">Distribution</p><p dir="ltr">The mean volume of distribution (Vdarea) of cefdinir in adult subjects is 0.35 L/kg (&plusmn;0.29); in pediatric subjects (age 6 months to 12 years), cefdinir Vdarea is 0.67 L/kg (&plusmn;0.38). Cefdinir is 60% to 70% bound to plasma proteins in both adult and pediatric subjects; binding is independent of concentration.</p><p dir="ltr">Skin Blister</p><p dir="ltr">In adult subjects, median (range) maximal blister fluid cefdinir concentrations of 0.65 (0.33 to 1.1) and 1.1 (0.49 to 1.9) mcg/mL were observed 4 to 5 hours following administration of 300 and 600 mg doses, respectively. Mean (&plusmn;SD) blister Cmax and AUC (0-&infin;) values were 48% (&plusmn;13) and 91% (&plusmn;18) of corresponding plasma values.</p><p dir="ltr">Tonsil Tissue</p><p dir="ltr">In adult patients undergoing elective tonsillectomy, respective median tonsil tissue cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were 0.25 (0.22</p><p dir="ltr">to 0.46) and 0.36 (0.22 to 0.80) mcg/g. Mean tonsil tissue concentrations were 24% (&plusmn;8) of corresponding plasma concentrations.</p><p dir="ltr">Sinus Tissue</p><p dir="ltr">In adult patients undergoing elective maxillary and ethmoid sinus surgery, respective median sinus tissue cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were &lt; 0.12 (&lt; 0.12 to 0.46) and 0.21 (&lt; 0.12 to 2.0) mcg/g. Mean sinus tissue concentrations were 16% (&plusmn;20) of corresponding plasma concentrations.</p><p dir="ltr">Lung Tissue</p><p dir="ltr">In adult patients undergoing diagnostic bronchoscopy, respective median bronchial mucosa cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were 0.78 (&lt; 0.06 to 1.33) and 1.14 (&lt; 0.06 to 1.92) mcg/mL, and were 31% (&plusmn;18) of corresponding plasma concentrations. Respective median epithelial lining fluid concentrations were 0.29 (&lt;</p><p dir="ltr">0.3 to 4.73) and 0.49 (&lt; 0.3 to 0.59) mcg/mL, and were 35% (&plusmn;83) of corresponding plasma concentrations.</p><p dir="ltr">Middle Ear Fluid</p><p dir="ltr">In 14 pediatric patients with acute bacterial otitis media, respective median middle ear fluid cefdinir concentrations 3 hours after administration of single 7 and 14 mg/kg doses were 0.21 (&lt; 0.09 to 0.94) and 0.72 (0.14 to 1.42) mcg/mL. Mean middle ear fluid concentrations were</p><p dir="ltr">15% (&plusmn;15) of corresponding plasma concentrations.</p><p dir="ltr">CSF</p><p dir="ltr">Data on cefdinir penetration into human cerebrospinal fluid are not available.</p><p dir="ltr">Metabolism and Excretion</p><p dir="ltr">Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t1/2) of 1.7 (&plusmn;0.6) hours. In healthy subjects with normal renal function, renal clearance is 2.0 (&plusmn;1.0) mL/min/kg, and apparent oral clearance is 11.6 (&plusmn;6.0) and 15.5 (&plusmn;5.4) mL/min/kg following doses of 300 and 600 mg, respectively. Mean percent of dose recovered unchanged in the urine following 300 and 600 mg doses is 18.4% (&plusmn;6.4) and&nbsp; 11.6% (&plusmn;4.6), respectively. Cefdinir clearance is reduced in patients with renal dysfunction.</p><p dir="ltr">Because renal excretion is the predominant pathway of elimination, dosage should be adjusted in patients with markedly compromised renal function or who are undergoing hemodialysis.</p><p dir="ltr"><strong>Special Populations</strong></p><p dir="ltr"><strong>Patients</strong><strong> </strong><strong>with Renal Insufficiency</strong></p><p dir="ltr">Cefdinir pharmacokinetics were investigated in 21 adult subjects with varying degrees of renal function. Decreases in cefdinir elimination rate, apparent oral clearance (CL/F), and renal clearance were approximately proportional to the reduction in creatinine clearance (CLcr). As a result, plasma cefdinir concentrations were higher and persisted longer in subjects with renal impairment than in those without renal impairment. In subjects with CLcr between 30 and 60 mL/min, Cmax and t1/2 increased&nbsp;by approximately 2-fold and AUC by approximately</p><p dir="ltr">3-fold.&nbsp;In subjects with CLcr&lt; 30 mL/min, Cmax increased&nbsp;by approximately 2-fold, t1/2 by&nbsp;approximately 5-fold, and AUC by approximately 6-fold. Dosage adjustment is recommended in patients with markedly compromised renal function (creatinine clearance &lt; 30 mL/min).</p><p dir="ltr"><strong>Hemodialysis</strong></p><p dir="ltr">Cefdinir pharmacokinetics were studied in 8 adult subjects undergoing hemodialysis. Dialysis (4 hours duration) removed 63% of cefdinir from the body and reduced apparent elimination t1/2 from 16 (&plusmn;3.5) to 3.2 (&plusmn;1.2) hours. Dosage adjustment is recommended in this patient population.</p><p dir="ltr"><strong>Hepatic Disease</strong></p><p dir="ltr">Because cefdinir is predominantly renally eliminated and not appreciably metabolized, studies in patients with hepatic&nbsp; impairment were not conducted.&nbsp; It is not expected that&nbsp; dosage adjustment will be required in this population.</p><p dir="ltr"><strong>Geriatric Patients</strong></p><p dir="ltr">The effect of age on cefdinir pharmacokinetics after a single 300 mg dose was evaluated in 32 subjects 19 to 91 years of age. Systemic exposure to cefdinir was substantially increased in older subjects (N=16), Cmax by 44% and AUC by 86%. This increase was due to a reduction in cefdinir clearance. The apparent volume of distribution was also reduced, thus no appreciable alterations in apparent elimination t1/2 were observed (elderly: 2.2 &plusmn; 0.6 hours vs young: 1.8 &plusmn; 0.4 hours). Since cefdinir clearance has been shown to be primarily related to changes in renal function rather than age, elderly patients do not require dosage adjustment unless they have markedly compromised renal function (creatinine clearance &lt; 30 mL/min, see PATIENTS WITH RENAL INSUFFICIENCY, above).</p><p dir="ltr"><strong>Gender and Race</strong></p><p dir="ltr">The results of a meta-analysis of clinical pharmacokinetics (N=217) indicated no significant impact of either gender or race on cefdinir pharmacokinetics.</p><p dir="ltr"><strong>Microbiology</strong></p><p dir="ltr">As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall</p><p dir="ltr">synthesis. Cefdinir is stable in the presence of some, but not all, &beta;-lactamase enzymes. As aresult, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.</p><p dir="ltr">Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in INDICATIONS AND USAGE.</p><p dir="ltr"><strong>Aerobic Gram-Positive Microorganisms</strong></p><p dir="ltr">Staphylococcus aureus (including &beta;-lactamase producing strains) NOTE: Cefdinir is inactive against methicillin-resistant staphylococci. Streptococcus pneumoniae (penicillin-susceptible strains only) Streptococcus pyogenes</p><p dir="ltr"><strong>Aerobic Gram-Negative Microorganisms</strong></p><p dir="ltr">Haemophilusinfluenzae (including &beta;-lactamase producing strains) Haemophilusparainfluenzae (including &beta;-lactamase producing strains) Moraxella catarrhalis (including &beta;-lactamase producing strains)</p><p dir="ltr">The following in vitro data are available, but their clinical significance is unknown.</p><p dir="ltr">Cefdinir exhibits in vitro minimum inhibitory concentrations (MICs) of 1 mcg/mL or less against (&ge; 90%) strains of the following microorganisms; however, the safety and effectiveness of cefdinir in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p><p dir="ltr"><strong>Aerobic Gram-Positive Microorganisms</strong></p><p dir="ltr">Staphylococcus epidermidis (methicillin-susceptible strains only) Streptococcus agalactiae</p><p dir="ltr">Viridans group streptococci</p><p dir="ltr">NOTE:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cefdinir&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inactive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; against Enterococcus and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methicillin- resistant Staphylococcus species.</p><p dir="ltr"><strong>Aerobic Gram-Negative Microorganisms</strong></p><p dir="ltr">Citrobacter diversus Escherichia coli Klebsiella pneumoniae Proteus mirabilis</p><p dir="ltr">NOTE: Cefdinir is inactive against Pseudomonas and Enterobacter species.</p><p dir="ltr"><strong>Susceptibility Tests </strong></p><p dir="ltr"><strong>Dilution Techniques</strong></p><p dir="ltr">Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method(1) (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefdinir powder. The MIC values should be interpreted according to the following criteria:</p><p dir="ltr"><strong>For organisms other than Haemophilus spp. and Streptococcus spp:</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" dir="ltr"><tbody><tr><td><p>MIC (mcg/mL)</p></td><td><p>Interpretation</p></td></tr><tr><td><p>&le; 1</p></td><td><p>Susceptible (S)</p></td></tr><tr><td><p>2</p></td><td><p>Intermediate (I)</p></td></tr><tr><td><p>&ge; 4</p></td><td><p>Resistant (R)</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>For Haemophilus spp:*</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" dir="ltr"><tbody><tr><td><p>MIC (mcg/mL)</p></td><td><p>Interpretation</p></td></tr><tr><td><p>&le; 1</p></td><td><p>Susceptible (S)</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">These interpretive standards are applicable only to broth microdilution susceptibility tests with Haemophilus spp. using Haemophilus Test Medium (HTM). (1)</p><p dir="ltr">&dagger; The current absence of data on resistant strains precludes defining any results other than &ldquo;Susceptible.&rdquo; Strains yielding MIC results suggestive of a &ldquo;nonsusceptible&rdquo; category should be submitted to a reference laboratory for further testing.</p><p dir="ltr">For Streptococcus spp:</p><p dir="ltr">Streptococcus pneumoniae that are susceptible to penicillin (MIC &le; 0.06 mcg/mL), or streptococci other than S. pneumoniae that are susceptible to penicillin (MIC &le; 0.12 mcg/mL), can be considered susceptible to cefdinir. Testing of cefdinir against penicillin-intermediate or penicillin-resistant isolates is not recommended. Reliable interpretive criteria for cefdinir are not available.</p><p dir="ltr">A report of &ldquo;Susceptible&rdquo; indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of &ldquo;Intermediate&rdquo; indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of &ldquo;Resistant&rdquo; indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p><p dir="ltr">Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. Standard cefdinir powder should provide the following MIC values:</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Microorganism</strong></p></td><td><p><strong>MIC</strong><strong> </strong><strong>Range</strong><strong> </strong><strong>(mcg/mL)</strong></p></td></tr><tr><td><p>Escherichia coli ATCC 25922</p></td><td><p>0.12-0.5</p></td></tr><tr><td><p>Haemophilusinfluenzae ATCC 49766*</p></td><td><p>0.12-0.5</p></td></tr><tr><td><p>Staphylococcus aureus ATCC 29213</p></td><td><p>0.12-0.5</p></td></tr></tbody></table><p dir="ltr">*This quality control range is applicable only to H. influenzae ATCC 49766 tested by a broth microdilution procedure using HTM.</p><p dir="ltr">Diffusion Techniques</p><p dir="ltr">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure(2)requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5 mcg cefdinir to test the susceptibility of microorganisms to cefdinir.</p><p dir="ltr">Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg cefdinir disk should be interpreted according to the following criteria:</p><p dir="ltr"><strong>For organisms other than Haemophilus spp. and Streptococcus spp:*</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Zone Diameter (mm)</strong></p></td><td><p><strong>Interpretation</strong></p></td></tr><tr><td><p>&ge; 20</p></td><td><p>Susceptible (S)</p></td></tr><tr><td><p>17-19</p></td><td><p>Intermediate (I)</p></td></tr><tr><td><p>&le; 16</p></td><td><p>Resistant (R)</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">*Because certain strains of Citrobacter, Providencia, and Enterobacter spp. have beenreported to give false susceptible results with the cefdinir disk, strains of these genera should not be tested and reported with this disk.</p><p dir="ltr"><strong>For Haemophilus spp:*</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Zone Diameter (mm)</strong></p></td><td><p><strong>Interpretation</strong></p></td></tr><tr><td><p>&ge; 20</p></td><td><p>Susceptible (S)</p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr">*These zone diameter standards are applicable only to tests with Haemophilusspp. using HTM.(2)</p><p dir="ltr">&dagger;The current absence of data on resistant strains precludes defining any results other than &ldquo;Susceptible.&rdquo; Strains yielding MIC results suggestive of a &ldquo;nonsusceptible&rdquo; category should be submitted to a reference laboratory for further testing.</p><p dir="ltr">For Streptococcusspp:</p><p dir="ltr">Isolates of Streptococcus pneumoniae should be tested against a 1 mcg oxacillin disk. Isolates with oxacillin zone sizes &ge; 20 mm are susceptible to penicillin and can be considered susceptible to cefdinir. Streptococci other than S. pneumoniae should be tested with a 10-unit penicillin disk. Isolates with penicillin zone sizes &ge; 28 mm are susceptible to penicillin and can be considered susceptible to cefdinir.</p><p dir="ltr">As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. For the diffusion technique, the 5 mcg cefdinir disk should provide the following zone diameters in these laboratory quality control strains:</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td><p><strong>Interpretation</strong></p></td><td><p><strong>Zone Diameter (mm)</strong></p></td></tr><tr><td><p>Escherichia coli ATCC 25922</p></td><td><p>24-28</p></td></tr><tr><td><p>Haemophilusinfluenzae ATCC 49766<u>*</u></p></td><td><p>24-31</p></td></tr><tr><td><p>Staphylococcus aureus ATCC 25923</p></td><td><p>25-32</p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr">*This quality control range is applicable only to testing of H. influenzae ATCC 49766 using HTM.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable in aapproved PIL in SFDA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>For capsules </strong>are microcrystalline cellulose, sodium lauryl sulphate, croscarmellose sodium, magnesium stearate.</p><p dir="ltr"><strong>For powder for oral suspension </strong>are Sucrose, methyl paraben (fine), xanthan gum, microcrystalline cellulose &amp; Carboxymethyl cellulose sodium, citric acid.H2O (fine), tutti fruiti powder flavor, FD&amp;C Red # 40, polysorbate 20, simethicone oil LVA, colloidal silicon dioxide, Isopropanol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store below 30&deg;C.</p><p dir="ltr">After reconstitution, the suspension should be used within 14 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Denacif</strong><strong>&reg;</strong><strong>&nbsp;</strong><strong>300</strong><strong> </strong><strong>mg</strong><strong> </strong><strong>Capsules</strong></p><p dir="ltr">Hard gelatin capsule with black opaque cap printed in white color with MD, Red opaque body printed in white color with Denacif 300, size zero, intended for oral use.</p><p dir="ltr"><strong><u>Pack size:</u></strong></p><p dir="ltr">10 capsules in HDPE bottle.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Denacif&reg;&nbsp;Powder for Oral Suspension</strong></p><p dir="ltr">Dry state: peach to light pink granules with tutti fruity flavor Reconstituted powder: pink suspension with tutti fruity flavor. <strong>&nbsp;</strong></p><p dir="ltr"><strong><u>Pack size:</u></strong></p><p dir="ltr">50 ml and 100 ml.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: Pharma International Company - Jordan 
Packed by: Med City Pharma - KSA
MAH is: Med City Pharma - KSA Tel: 00966920003288
Fax: 00966126358138
Mobile: 00966555786968
P.O .Box: 42512 - Jeddah 21551 E-mail: MD.admin@axantia.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>